Total Payments
$2,051
2024 Payments
$400.85
Companies
37
Transactions
105
Medicare Patients
1,799
Medicare Billing
$222,239
Payment Breakdown by Category
Food & Beverage$1,995 (97.3%)
Education$56.00 (2.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,995 | 103 | 97.3% |
| Education | $56.00 | 2 | 2.7% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $179.05 | 8 | $0 (2024) |
| PFIZER INC. | $176.02 | 9 | $0 (2024) |
| Amgen Inc. | $172.12 | 8 | $0 (2023) |
| Janssen Biotech, Inc. | $163.81 | 10 | $0 (2024) |
| Genentech USA, Inc. | $148.21 | 8 | $0 (2023) |
| Merck Sharp & Dohme LLC | $125.44 | 7 | $0 (2023) |
| Daiichi Sankyo Inc. | $102.37 | 5 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $98.56 | 5 | $0 (2019) |
| Seattle Genetics, Inc. | $84.60 | 4 | $0 (2019) |
| ABBVIE INC. | $82.06 | 3 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $400.85 | 17 | Daiichi Sankyo Inc. ($86.06) |
| 2023 | $235.49 | 11 | Mirati Therapeutics, Inc. ($40.51) |
| 2022 | $188.57 | 10 | Amgen Inc. ($46.39) |
| 2021 | $251.20 | 13 | Amgen Inc. ($41.90) |
| 2020 | $162.34 | 10 | Coherus Biosciences Inc. ($39.51) |
| 2019 | $327.30 | 17 | Novartis Pharmaceuticals Corporation ($67.61) |
| 2018 | $275.59 | 15 | Genentech USA, Inc. ($91.45) |
| 2017 | $209.89 | 12 | Novartis Pharmaceuticals Corporation ($30.40) |
All Payment Transactions
105 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | ABBVIE INC. | EPKINLY (Drug), IMBRUVICA | Food and Beverage | In-kind items and services | $24.30 | General |
| Category: ONCOLOGY | ||||||
| 11/05/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $31.89 | General |
| 08/20/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $21.42 | General |
| Category: ONCOLOGY | ||||||
| 08/12/2024 | ABBVIE INC. | EPKINLY (Drug), IMBRUVICA | Food and Beverage | In-kind items and services | $27.25 | General |
| Category: ONCOLOGY | ||||||
| 06/25/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), IMBRUVICA | Food and Beverage | In-kind items and services | $15.81 | General |
| Category: Oncology | ||||||
| 05/21/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $20.68 | General |
| Category: ONCOLOGY | ||||||
| 05/17/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $29.72 | General |
| Category: Oncology | ||||||
| 05/17/2024 | PFIZER INC. | ELREXFIO (Drug), ADCETRIS | Food and Beverage | In-kind items and services | $22.08 | General |
| Category: ONCOLOGY | ||||||
| 04/30/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $17.19 | General |
| Category: Oncology | ||||||
| 04/24/2024 | PFIZER INC. | ELREXFIO (Drug), ADCETRIS | Food and Beverage | In-kind items and services | $21.37 | General |
| Category: ONCOLOGY | ||||||
| 03/27/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), IMBRUVICA | Food and Beverage | In-kind items and services | $15.82 | General |
| Category: Oncology | ||||||
| 03/20/2024 | PFIZER INC. | ELREXFIO (Drug) | Food and Beverage | In-kind items and services | $21.44 | General |
| Category: ONCOLOGY | ||||||
| 03/19/2024 | ABBVIE INC. | EPKINLY (Drug), IMBRUVICA | Food and Beverage | In-kind items and services | $30.51 | General |
| Category: ONCOLOGY | ||||||
| 02/09/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $24.03 | General |
| Category: ONCOLOGY | ||||||
| 01/30/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $19.93 | General |
| Category: ONCOLOGY | ||||||
| 01/11/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ICLUSIG (Drug) | Food and Beverage | In-kind items and services | $34.24 | General |
| Category: ONCOLOGY | ||||||
| 01/03/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI, TALVEY | Food and Beverage | In-kind items and services | $23.17 | General |
| Category: Oncology | ||||||
| 10/26/2023 | Novartis Pharmaceuticals Corporation | PIQRAY (Drug), KISQALI | Food and Beverage | In-kind items and services | $35.65 | General |
| Category: Oncology | ||||||
| 10/24/2023 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), LYNPARZA | Food and Beverage | In-kind items and services | $24.72 | General |
| Category: ONCOLOGY | ||||||
| 08/03/2023 | Genentech USA, Inc. | Venclexta (Biological) | Food and Beverage | In-kind items and services | $22.59 | General |
| Category: BioOncology | ||||||
| 05/12/2023 | Seagen Inc. | ADCETRIS (Biological) | Food and Beverage | In-kind items and services | $23.77 | General |
| Category: Oncology | ||||||
| 05/12/2023 | PFIZER INC. | IBRANCE (Drug) | Food and Beverage | In-kind items and services | $13.57 | General |
| Category: ONCOLOGY | ||||||
| 05/09/2023 | Amgen Inc. | Blincyto (Biological), Kyprolis | Food and Beverage | In-kind items and services | $14.66 | General |
| Category: Oncology | ||||||
| 04/27/2023 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Food and Beverage | Cash or cash equivalent | $20.45 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 04/26/2023 | Janssen Biotech, Inc. | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $16.98 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 448 | 712 | $210,466 | $57,622 |
| 2022 | 7 | 383 | 532 | $135,114 | $45,188 |
| 2021 | 9 | 510 | 768 | $186,039 | $69,570 |
| 2020 | 9 | 458 | 680 | $158,962 | $49,859 |
Total Patients
1,799
Total Services
2,692
Medicare Billing
$222,239
Procedure Codes
31
All Medicare Procedures & Services
31 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 83 | 193 | $73,437 | $20,808 | 28.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 117 | 186 | $52,677 | $13,260 | 25.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 159 | 197 | $39,558 | $9,128 | 23.1% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 46 | 57 | $26,028 | $7,772 | 29.9% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 23 | 53 | $14,047 | $5,035 | 35.8% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 20 | 26 | $4,719 | $1,619 | 34.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 85 | 163 | $50,832 | $18,068 | 35.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 119 | 156 | $35,630 | $10,718 | 30.1% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 34 | 38 | $15,641 | $5,873 | 37.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 86 | 91 | $14,538 | $3,932 | 27.0% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 24 | 42 | $8,940 | $3,392 | 37.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 12 | 12 | $5,079 | $1,611 | 31.7% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 23 | 30 | $4,454 | $1,592 | 35.8% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 87 | 198 | $57,024 | $22,521 | 39.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 151 | 241 | $51,815 | $17,543 | 33.9% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 63 | 70 | $27,790 | $11,259 | 40.5% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 36 | 72 | $14,616 | $6,013 | 41.1% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 96 | 102 | $14,994 | $4,777 | 31.9% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 25 | 25 | $10,250 | $3,572 | 34.8% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 26 | 32 | $4,512 | $1,833 | 40.6% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 14 | 15 | $4,050 | $1,649 | 40.7% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2021 | 12 | 13 | $988.00 | $403.39 | 40.8% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 144 | 286 | $61,490 | $17,310 | 28.2% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 59 | 114 | $32,832 | $9,849 | 30.0% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 31 | 35 | $13,895 | $5,623 | 40.5% |
About Dr. Navin Wadehra, MD
Dr. Navin Wadehra, MD is a Hematology & Oncology healthcare provider based in Douglasville, Georgia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/09/2006. The National Provider Identifier (NPI) number assigned to this provider is 1396755385.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Navin Wadehra, MD has received a total of $2,051 in payments from pharmaceutical and medical device companies, with $400.85 received in 2024. These payments were reported across 105 transactions from 37 companies. The most common payment nature is "Food and Beverage" ($1,995).
As a Medicare-enrolled provider, Wadehra has provided services to 1,799 Medicare beneficiaries, totaling 2,692 services with total Medicare billing of $222,239. Data is available for 4 years (2020–2023), covering 31 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Douglasville, GA
- Active Since 08/09/2006
- Last Updated 04/17/2019
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1396755385
Products in Payments
- IMBRUVICA (Drug) $116.13
- ADCETRIS (Biological) $108.37
- KEYTRUDA (Biological) $106.66
- DARZALEX (Biological) $88.54
- Perjeta (Biological) $86.47
- Enhertu (Drug) $86.06
- EPKINLY (Drug) $82.06
- OPDIVO (Biological) $79.52
- Kyprolis (Drug) $68.50
- ELREXFIO (Drug) $64.89
- PIQRAY (Drug) $57.52
- BOSULIF (Drug) $47.94
- Nplate (Biological) $46.54
- KRAZATI (Drug) $40.51
- MEKINIST (Drug) $39.92
- Stivarga (Drug) $39.91
- Udenyca (Biological) $39.51
- ICLUSIG (Drug) $34.24
- TAZVERIK (Drug) $34.21
- KISQALI (Drug) $29.72
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Douglasville
Rohini Chintalapally, Md, MD
Hematology & Oncology — Payments: $8,074
Hematology & Oncology $8,074
Dr. Kristy Mcdonald-Grimm, M.d, M.D
Hematology & Oncology — Payments: $4,229
Hematology & Oncology $4,229
Dr. Deepti Munjal, Md, MD
Hematology & Oncology — Payments: $1,043
Hematology & Oncology $1,043